Press release
Exosomes Pipeline, Clinical Trials Assessment, NDA Approvals in 2023
Exosomes Pipeline
In the Exosomes pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Exosomes clinical trials studies, Exosomes NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Exosomes Pipeline Insight Report
• Over 60+ Exosomes companies are evaluating 110+ Exosomes pipeline therapies in various stages of development, and their anticipated acceptance in the Exosomes market would significantly increase market revenue.
• The leading Exosomes Companies include Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, Ilias, ReNeuron, Evora Biosciences, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
• Promising Exosomes Pipeline Therapies includes ExoIntelliScore Prostate, MSCs-derived Exosomes, Test: ExoDx Prostate(IntelliScore), Zofin, ExoFlo, Intravenous normal saline, Olmutinib, and others.
• The Exosomes companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The Exosomes pipeline therapies under development are focused on novel approaches to treat/improve Exosomes.
To explore more information on the latest breakthroughs in the Exosomes Pipeline treatment landscape of the report, click here @ Exosomes Pipeline Outlook- https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Exosomes Overview
An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.
Latest Breakthroughs or News of the Exosomes Treatment Landscape
• In 2022, Bio-Techne and Thermo Fisher Scientific came to an agreement for the creation of the ExoTRU kidney transplant rejection test. Information about the health of the allografts that can be used in clinical settings will be provided by this test.
• In 2020, Lonza purchased Codiak Biosciences' exosome facility. The latter retains its exosome drug-loading technologies and therapeutic candidate pipeline.
For further information, refer to the detailed Exosomes Unmet Needs, Exosomes Market Drivers, and Exosomes Market Barriers, click here for Exosomes Ongoing Clinical Trial Analysis- https://www.delveinsight.com/report-store/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Exosomes Emerging Drugs Profile
• CAP-1002: Capricor
Capricor's (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor's scientific founder, Dr. Eduardo Marbán. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of Duchenne Muscular Dystrophy.
• Progenza: Regeneus
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing.
• AGLE 102: Aegle Therapeutics
AGLE 102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerative healing factors to diseased and damaged tissue.It is being developed by Aegle Therapeutics for Dystrophic Epidermolysis Bullosa.
• Zofin: Organicell Regenerative Medicine
Zofin is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
• Exo-101: Exogenus Therapeutics
Exogenus developed a product Exo-101, based on vesicles released by mononuclear cells from umbilical cord blood, which shows promise for regenerative medicine (namely healing of chronic wounds) and inflammatory diseases. Known for their capacity to travel long distances within the body and support cellular communication, these nano-sized vesicles are also thought to be safer than cellular therapies, while maintaining similar efficacy. Due to its immunomodulatory properties, Exo-101 is being explored for inflammatory skin diseases, such as psoriasis. The combination of pro-regenerative and anti-inflammatory potential of Exo-101 may benefit patients with inflammatory lung diseases, including COVID-19-related respiratory complications. Exo-101 has been shown to accelerate the healing of chronic wounds.
• COYA 201: Coya Therapeutics
COYA 201 product candidate utilizes Treg-derived exosome therapeutic modality. For COYA 201, the company is currently completing animal model studies and will conduct pharmacology, toxicology and other IND-enabling studies to support the initiation of clinical trials in neurodegenerative, autoimmune and metabolic diseases.
Exosomes Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.
Request a sample and discover the recent advances in Exosomes Ongoing Clinical Trial Analysis and Medications, click here @ Exosomes Treatment Landscape- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Exosomes Pipeline Insight Report
• Coverage- Global
• Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
• Exosomes Pipeline Therapies- ExoIntelliScore Prostate, MSCs-derived Exosomes, Test: ExoDx Prostate(IntelliScore), Zofin, ExoFlo, Intravenous normal saline, Olmutinib, and others.
• Exosomes Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Exosomes Market Drivers and H Exosomes Market Barriers, click here @ Exosomes Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Exosomes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Exosomes- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAP-1002: Capricor
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Progenza: Regeneus
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. StemXO Endosome Therapy: Stem XO Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Exo-101: Exogenus Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Exosome - Collaborations Assessment- Licensing / Partnering / Funding
21. Exosomes- Unmet Needs
22. Exosomes- Market Drivers and Barriers
23. Appendix
Got Queries? Find out the related information on Exosomes Mergers and acquisitions, Exosomes Licensing Activities @ Exosomes Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/out-licensing-opportunity
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exosomes Pipeline, Clinical Trials Assessment, NDA Approvals in 2023 here
News-ID: 3108823 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Exosome
Spotlight on Exosome Delivery Technology - Creative Biolabs Showcased at the 202 …
On September 25, 2025, the multi-day 7th Exosome-Based Therapeutic Development Summit concluded successfully.
New York, USA - October 13, 2025 - During the presentations and panel discussions, participants noted the special benefits exosomes bring-including excellent biocompatibility, low immunogenicity, and the ability to cross biological barriers-reiterating their great promise in cancer treatment, neurological disorders, and immune regulation. When compared with liposomes and traditional nanoparticles, exosomes offer greater efficiencies in carrying nucleic acids,…
Emerging Trends to Reshape the Exosome Technologies Market: Creative Biolabs Lau …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Exosome Technologies Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the exosome technologies market size has seen a significant exponential growth. The market is projected to expand from $0.07 billion in 2024 to $0.09 billion in 2025, with a compound…
Exosome Therapy Market May See a Big Move | Major Giants- Exiqon, Exosome Diagno …
HTF MI recently introduced Global Exosome Therapy Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborating market size (2024-2031). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence.
The Major Players Covered in this Report: Sistemic Ltd Aethlon Medical, Inc. (United States), Exosome Diagnostic, Inc. (United States), Thermo Fisher Scientific, Inc. (United…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
Exosome Technologies Market Report 2024 - Exosome Technologies Market Size, Shar …
"The Business Research Company recently released a comprehensive report on the Global Exosome Technologies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The exosome technologies market size…
Exosome technologies Market Growth Expected to See Next Level | Exosome Diagnost …
The Latest Study Published by HTF MI Research on the "Exosome technologies Market'' evaluates market size, trend and forecast to 2030. The Exosome technologies market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges as well…
